We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Novel Antibody Obliterates Plaque Psoriasis

By HospiMedica International staff writers
Posted on 24 Aug 2014
Print article
New studies show that treatment of longstanding plaque psoriasis with secukinumab, a fully human anti-interleukin-17A monoclonal antibody, was associated with rapid and dramatic improvements.

Researchers at Dalhousie University (Halifax, NS, Canada), Mount Sinai Hospital (New York, NY, USA), and other institutions conducted two phase 3, double-blind, 52-week trials to examine the efficacy of secukinumab over placebo with regard to the proportion of patients who had a reduction of 75% or more from baseline in the Psoriasis Area-and-Severity Index (PASI 75), and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment scale. Both studies had a 3-month induction phase, a 40-week maintenance period, and a further eight weeks of follow-up.

The first study, ERASURE, which enrolled 738 patients, showed PASI 75 score improvements in 81.6% of patients receiving 300 mg secukinumab at three months, and in 71.6% of those given 150 mg, compared with 4.5% of those randoizedm to placebo. In the second study, FIXTURE, which enrolled 1,306 patients, PASI 75 responses at 3 months were reported for 77.1% of the 300 mg secukinumab group, 67% of the 150 mg group, 44% of those receiving etanercept, and 4.9% of those given placebo. The study results were published on July 24, 2014, in the New England Journal of Medicine (NEJM).

“Secukinumab targets the proinflammatory cytokine interleukin 17A, which acts as a master cytokine in the pathogenesis of psoriasis,” concluded lead author Richard Langley, MD, of Dalhousie University, and colleagues. “Identifying that secukinumab blocks IL-17A is one of the most, if not the most, impressive results that we’ve seen to date in psoriasis research. Until now, we’ve not been able to identify the key players in the cause of this common skin condition.”

Psoriasis is a chronic skin condition with intermittent relapses characterized by patches, papules, and plaques, which usually itch. It is generally considered a genetic disease influenced by environmental factors, and affects approximately 1%–2% of the world’s population. Plaque psoriasis is the most common form, and typically manifests as red and white scaly patches. Skin cells rapidly accumulate at these plaque sites, creating silvery-white painful, itchy lesions. Psoriasis been linked to a host of health problems, including obesity arthritis, inflammatory bowel disease (IBD), hypertension, ischemic heart disease, and stroke.

Related Links:

Dalhousie University
Mount Sinai Hospital


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
High Power Laser System
Dornier Thulio

Print article

Channels

Surgical Techniques

view channel
Image: The Early Bird Bleed Monitoring System provides visual and audible indicators of the onset and progression of bleeding events (Photo courtesy of Saranas)

Novel Technology Monitors and Lowers Bleeding Complications in Patients Undergoing Heart Procedures

Bleeding complications at the femoral access site can significantly hamper recovery, affecting the success of procedures, patient satisfaction, and overall healthcare costs. It is crucial for surgeons... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The new eye-safe laser technology can diagnose traumatic brain injury (Photo courtesy of 123RF)

Novel Diagnostic Hand-Held Device Detects Known Biomarkers for Traumatic Brain Injury

The growing need for prompt and efficient diagnosis of traumatic brain injury (TBI), a major cause of mortality globally, has spurred the development of innovative diagnostic technologies.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.